Chapter 11 Archives • Page 3 of 4 • Children's Health Defense

61

J.B. Layton et al., “Prenatal Tdap Immunization and Risk of Maternal and Newborn Adverse Events,” Vaccine 35, no. 33 (2017): 4072–4078, doi:10.1016/j.vaccine.2017.06.071.

62

J.B. Layton et al., “Prenatal Tdap Immunization and Risk of Maternal and Newborn Adverse Events,” Vaccine 35, no. 33 (2017): 4072–4078, doi:10.1016/j.vaccine.2017.06.071.

63

J.B. Layton et al., “Prenatal Tdap Immunization and Risk of Maternal and Newborn Adverse Events,” Vaccine 35, no. 33 (2017): 4072–4078, doi:10.1016/j.vaccine.2017.06.071.

64

J.B. Layton et al., “Prenatal Tdap Immunization and Risk of Maternal and Newborn Adverse Events,” Vaccine 35, no. 33 (2017): 4072–4078, doi:10.1016/j.vaccine.2017.06.071.

65

J.B. Layton et al., “Prenatal Tdap Immunization and Risk of Maternal and Newborn Adverse Events,” Vaccine 35, no. 33 (2017): 4072–4078, doi:10.1016/j.vaccine.2017.06.071.

66

J.B. Layton et al., “Prenatal Tdap Immunization and Risk of Maternal and Newborn Adverse Events,” Vaccine 35, no. 33 (2017): 4072–4078, doi:10.1016/j.vaccine.2017.06.071.

67

Malini DeSilva et al., “Maternal Tdap Vaccination and Risk of Infant Morbidity,” Vaccine 35, no. 29 (2017): 3655-3660, doi:10.1016/j.vaccine.2017.05.041.

68

Malini DeSilva et al., “Maternal Tdap Vaccination and Risk of Infant Morbidity,” Vaccine 35, no. 29 (2017): 3655-3660, doi:10.1016/j.vaccine.2017.05.041.

69

Pedro Moro et al., “Enhanced Surveillance of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in Pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015,” Vaccine 34, no. 20 (2016): 2349–2353, doi:10.1016/j.vaccine.2016.03.049.

70

Pedro Moro et al., “Enhanced Surveillance of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in Pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015,” Vaccine 34, no. 20 (2016): 2349–2353, doi:10.1016/j.vaccine.2016.03.049.

71

Pedro Moro et al., “Enhanced Surveillance of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccines in Pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015,” Vaccine 34, no. 20 (2016): 2349–2353, doi:10.1016/j.vaccine.2016.03.049.

72

Malini De Silva et al., “Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy,” The New England Journal of Medicine 387, no. 2 (2022): 187–189, doi:10.1056/NEJMc2205276.

73

US Food and Drug Administration, Comirnaty®: Package Insert, (New York, NY: Pfizer Inc., 2021).

74

“Covid-19 Vaccines While Pregnant or Breastfeeding,” Centers for Disease Control and Prevention, updated October 20, 2022.

75

Malini De Silva et al., “Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy,” The New England Journal of Medicine 387, no. 2 (2022): 187–189, doi:10.1056/NEJMc2205276.

76

Aharon Dick et al., “Safety of Third SARS-CoV-2 Vaccine (Booster Dose) During Pregnancy,” American Journal of Obstetrics & Gynecology MFM 4, no.4 (2022): 100637, doi:10.1016/j.ajogmf.2022.100637.

77

Aharon Dick et al., “Safety of Third SARS-CoV-2 Vaccine (Booster Dose) During Pregnancy,” American Journal of Obstetrics & Gynecology MFM 4, no.4 (2022): 100637, doi:10.1016/j.ajogmf.2022.100637.

78

Aharon Dick et al., “Safety of Third SARS-CoV-2 Vaccine (Booster Dose) During Pregnancy,” American Journal of Obstetrics & Gynecology MFM 4, no.4 (2022): 100637, doi:10.1016/j.ajogmf.2022.100637.

79

“Gestational Diabetes,” Centers for Disease Control and Prevention, accessed on April 16, 2023.

80

“VAERS Data,” Vaccine Adverse Event Reporting System (VAERS), updated April 7, 2023.

81

“VAERS Data,” Vaccine Adverse Event Reporting System (VAERS), updated April 7, 2023.

82

“VAERS Data,” Vaccine Adverse Event Reporting System (VAERS), updated April 7, 2023.

83

Itai Gat et al., “Covid-19 Vaccination BNT162b2 Temporarily Impairs Semen Concentration and Total Motile Count among Semen Donors,” Andrology 10, no. 6 (2022): 1016–1022, doi:10.1111/andr.13209.

84

Itai Gat et al., “Covid-19 Vaccination BNT162b2 Temporarily Impairs Semen Concentration and Total Motile Count among Semen Donors,” Andrology 10, no. 6 (2022): 1016–1022, doi:10.1111/andr.13209.

85

Itai Gat et al., “Covid-19 Vaccination BNT162b2 Temporarily Impairs Semen Concentration and Total Motile Count among Semen Donors,” Andrology 10, no. 6 (2022): 1016–1022, doi:10.1111/andr.13209.

86

Itai Gat et al., “Covid-19 Vaccination BNT162b2 Temporarily Impairs Semen Concentration and Total Motile Count among Semen Donors,” Andrology 10, no. 6 (2022): 1016–1022, doi:10.1111/andr.13209.

87

Stephanie A. Irving et al., “Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion,” Obstetrics and Gynecology 121, no. 1 (2013): 159–165, doi:10.1097/aog.0b013e318279f56f.

88

Gary S. Goldman, “Comparison of VAERS Fetal-Loss Reports During Three Consecutive Influenza Seasons: Was There a Synergistic Fetal Toxicity Associated with the Two-Vaccine 2009/2010 Season?,” Human & Experimental Toxicology 32, no. 5 (2012) 464–475. https://doi.org/10.1177/0960327112455067.

89

James G. Donahue et al, “Inactivated Influenza Vaccine and Spontaneous Abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15,” Vaccine 37, no.44 (2019): 6673–6681, doi:10.1016/j.vaccine.2019.09.035.

90

Alberto Donzelli, “Influenza Vaccination of Pregnant Women and Serious Adverse Events in the Offspring,” International Journal of Environmental Research and Public Health 16, no. 22 (2019): 4347, doi:10.3390/ijerph16224347.